Dr Reddy’s Laboratories Ltd has launched Tobramycin Inhalation Solution, a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).
The TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million for the twelve months ended April 2019 according to a release from IQVIA Health, the Hyderabad-based company.
Tobi is a trademark of Mylan. Dr Reddy’s Tobramycin Inhalation Solution is available in a 300 mg/5 mL, single-dose Ampule.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.